Tags

Type your tag names separated by a space and hit enter

Bolus administration of obestatin does not change glucose and insulin levels neither in the systemic nor in the portal circulation of the rat.
Peptides. 2008 Dec; 29(12):2144-9.P

Abstract

Obestatin is a second peptide derived from the preproghrelin polypeptide. It was originally thought to have anorexigenic effects, thereby functioning as an antagonist of ghrelin. However, this has been a subject of debate ever since. Since acylated ghrelin strongly induces insulin resistance, it could be hypothesized that obestatin plays a role in glucose homeostasis as well. In the present study we evaluated the effect of obestatin on glucose and insulin metabolism in the systemic and portal circulation. Obestatin 200 nmol/kg was administered systemically as a single intravenous bolus injection to fasted pentobarbital anesthetized adult male Wistar rats. Up to 50 min after administration, blood samples were taken to measure glucose and insulin concentrations, both in the portal and in the systemic circulation. The effect of obestatin was evaluated in fasted and in glucose-stimulated conditions (IVGTT) and compared to control groups treated with saline or IVGTT, respectively. Intravenous administration of obestatin did not have any effect on glucose and insulin concentrations, neither systemic nor portal, when compared to the control groups. Only the glucose peak 1 min after administration of IVGTT was slightly higher in the obestatin treated rats: 605.8+/-106.3% vs. 522.2+/-47.1% in the portal circulation, respectively (NS), and 800.7+/-78.7% vs. 549.6+/-37.0% in the systemic circulation, respectively (P<0.02), but it can be debated whether this has any clinical relevance. In the present study, we demonstrated that intravenously administered obestatin does not influence glucose and insulin concentrations, neither in the portal nor in the systemic circulation.

Authors+Show Affiliations

Department of Internal Medicine, Section of Endocrinology, Erasmus University Medical Centre, PO Box 2040, 3000 CA Rotterdam, The Netherlands. r.kiewiet@erasmusmc.nlNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

18930090

Citation

Kiewiet, Rosalie M., et al. "Bolus Administration of Obestatin Does Not Change Glucose and Insulin Levels Neither in the Systemic nor in the Portal Circulation of the Rat." Peptides, vol. 29, no. 12, 2008, pp. 2144-9.
Kiewiet RM, Gauna C, van Aken MO, et al. Bolus administration of obestatin does not change glucose and insulin levels neither in the systemic nor in the portal circulation of the rat. Peptides. 2008;29(12):2144-9.
Kiewiet, R. M., Gauna, C., van Aken, M. O., van de Zande, B., & van der Lely, A. J. (2008). Bolus administration of obestatin does not change glucose and insulin levels neither in the systemic nor in the portal circulation of the rat. Peptides, 29(12), 2144-9. https://doi.org/10.1016/j.peptides.2008.09.011
Kiewiet RM, et al. Bolus Administration of Obestatin Does Not Change Glucose and Insulin Levels Neither in the Systemic nor in the Portal Circulation of the Rat. Peptides. 2008;29(12):2144-9. PubMed PMID: 18930090.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Bolus administration of obestatin does not change glucose and insulin levels neither in the systemic nor in the portal circulation of the rat. AU - Kiewiet,Rosalie M, AU - Gauna,Carlotta, AU - van Aken,Maarten O, AU - van de Zande,Bedette, AU - van der Lely,Aart Jan, Y1 - 2008/09/26/ PY - 2008/08/05/received PY - 2008/09/18/revised PY - 2008/09/19/accepted PY - 2008/10/22/pubmed PY - 2009/2/20/medline PY - 2008/10/22/entrez SP - 2144 EP - 9 JF - Peptides JO - Peptides VL - 29 IS - 12 N2 - Obestatin is a second peptide derived from the preproghrelin polypeptide. It was originally thought to have anorexigenic effects, thereby functioning as an antagonist of ghrelin. However, this has been a subject of debate ever since. Since acylated ghrelin strongly induces insulin resistance, it could be hypothesized that obestatin plays a role in glucose homeostasis as well. In the present study we evaluated the effect of obestatin on glucose and insulin metabolism in the systemic and portal circulation. Obestatin 200 nmol/kg was administered systemically as a single intravenous bolus injection to fasted pentobarbital anesthetized adult male Wistar rats. Up to 50 min after administration, blood samples were taken to measure glucose and insulin concentrations, both in the portal and in the systemic circulation. The effect of obestatin was evaluated in fasted and in glucose-stimulated conditions (IVGTT) and compared to control groups treated with saline or IVGTT, respectively. Intravenous administration of obestatin did not have any effect on glucose and insulin concentrations, neither systemic nor portal, when compared to the control groups. Only the glucose peak 1 min after administration of IVGTT was slightly higher in the obestatin treated rats: 605.8+/-106.3% vs. 522.2+/-47.1% in the portal circulation, respectively (NS), and 800.7+/-78.7% vs. 549.6+/-37.0% in the systemic circulation, respectively (P<0.02), but it can be debated whether this has any clinical relevance. In the present study, we demonstrated that intravenously administered obestatin does not influence glucose and insulin concentrations, neither in the portal nor in the systemic circulation. SN - 0196-9781 UR - https://www.unboundmedicine.com/medline/citation/18930090/Bolus_administration_of_obestatin_does_not_change_glucose_and_insulin_levels_neither_in_the_systemic_nor_in_the_portal_circulation_of_the_rat_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0196-9781(08)00403-8 DB - PRIME DP - Unbound Medicine ER -